Titan Medical Inc.

As of June 30, 2024, Titan Medical Inc. has 114.04M shares outstanding.

As of June 30, 2024, Titan Medical Inc. trades at a trailing price-to-earnings ratio of 29.73. The price-to-sales ratio is 109.38, and the price-to-book ratio stands at -4.11.

As of June 30, 2024, Titan Medical Inc. trades at an EV/EBITDA multiple of 10,911.63 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 106.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.55 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Titan Medical Inc. trades at an EV/FCF ratio of 26.45, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2024, Titan Medical Inc. maintains a current ratio of 3.73, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.23, indicating elevated leverage, while an interest coverage ratio of -14.83 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -58.12, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -1.52, pointing to unprofitable operations over the period.

Over the twelve months ended June 30, 2024, Titan Medical Inc. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -240.53 and net profit margin of -531.26 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Free cash flow yield is negative at -5.65: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.56, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Titan Medical Inc. shareholders.

Titan Medical Inc.'s most recent stock split took place on June 19, 2018 with a 30:1 split ratio.

As of June 30, 2024, Titan Medical Inc. has an Altman Z-Score of -56.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.